Loading
MCLA-129 is an experimental bispecific antibody from Betta Pharmaceuticals in phase 2 trials for non-small-cell lung cancer, head and neck squamous cell carcinoma and colorectal cancer, aimed at EGFR and MET.
MCLA-129 is a bispecific antibody developed by Betta Pharmaceuticals and Merus. Its targets are EGFR and MET (the sponsor names EGFR x c-Met). The sponsor states: A human bispecific antibody targeting both EGFR and c-Met, simultaneously blocking the signalling pathways of both receptors to inhibit tumour growth and survival. ClinicalTrials.gov describes the intervention as: MCLA-129 is a bispecific antibody that targets both EGFR and c-Met, simultaneously blocking the signaling pathways of both EGFR and c-Met, thereby inhibiting tumour growth and survival. It is the investigational product in 3 recruiting or active industry-led phase 2 and phase 3 interventional cancer trials, in non-small-cell lung cancer, head and neck squamous cell carcinoma, colorectal cancer, gastric & gastro-oesophageal junction cancer and oesophageal cancer. The largest, NCT04930432, plans to enrol 400 participants with primary completion expected 2028-04-30. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.
1.One arm of MCLA-129 binds EGFR on the cancer cell.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"MCLA-129" OR ABSTRACT:"MCLA-129" OR TITLE:"bispecific" OR ABSTRACT:"bispecific") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about MCLA-129, not a curated reading list.
Shares Gastric & gastro-oesophageal junction cancer, Head and neck squamous cell carcinoma, Colorectal cancer, Non-small-cell lung cancer and the tag pipeline.
Shares Oesophageal cancer, Gastric & gastro-oesophageal junction cancer, Head and neck squamous cell carcinoma, Non-small-cell lung cancer and the tag pipeline.
Shares Oesophageal cancer, Gastric & gastro-oesophageal junction cancer, Head and neck squamous cell carcinoma, Colorectal cancer and the tag pipeline.
Shares Genmab, Head and neck squamous cell carcinoma, Colorectal cancer, Non-small-cell lung cancer and the tag pipeline.
Shares MET, EGFR, Oesophageal cancer, Non-small-cell lung cancer and the tag pipeline.
Shares MET, EGFR, Colorectal cancer and the tag pipeline.
Shares MET, EGFR, Non-small-cell lung cancer and the tag pipeline.
Shares MET, EGFR, Non-small-cell lung cancer and the tag pipeline.